Constellation Pharmaceuticals, which is developing epigenetic cancer therapies that modulate abnormal genes, announced terms for its IPO on Monday.
The Cambridge, MA-based company plans to raise $80 million by offering 5.3 million shares at a price range of $14 to $16. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, Constellation Pharmaceuticals would command a fully diluted market value of $430 million.
Constellation Pharmaceuticals was founded in 2008 and booked n/a in sales for the 12 months ended March 31, 2018. It plans to list on the Nasdaq under the symbol CNST. J.P. Morgan, Jefferies and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of July 16, 2018.
